Komori
Share Issuance and Disposal4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Adjustment of the Conversion Price of Euro-Yen Convertible Bonds with Stock Acquisition Rights Due 2032

The conversion price of the Euro-Yen convertible bonds with stock acquisition rights due 2032 was reduced from ¥2,828.5 to ¥2,817.2 following the determination of the dividend. The adjustment will apply from 1 April 2026.

Worth reading
19Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
11.3
Yen (reduction in the conversion price per share)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Terms of the stock acquisition rights
Exercise price
Initial conversion price: ¥2,828.5; adjusted conversion price: ¥2,817.2. Details of the adjustment provisions and the floor are Not disclosed
Details of issuance or disposal
ItemDetails
Exercise priceInitial conversion price: ¥2,828.5; adjusted conversion price: ¥2,817.2. Details of the adjustment provisions and the floor are Not disclosed
Items this document does not state (27)
Type of issuance or disposalNumber of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The adjustment was made in accordance with the conversion price adjustment provisions following the determination of the annual dividend for the fiscal year ending March 2026 at ¥46 per share, including a year-end dividend of ¥25.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Adjustment of the Conversion Price of Euro-Yen Convertible Bonds with Stock Acquisition Rights Due 2032 | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori